Jubilant Life Sciences is currently trading at Rs. 144.60, up by 7.60 points or 5.55% from its previous closing of Rs. 137.00 on the BSE.
The scrip opened at Rs. 143.00 and has touched a high and low of Rs. 147.50 and Rs. 141.55 respectively. So far 78,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 190.00 on 12-Mar-2013 and a 52 week low of Rs. 65.10 on 28-Aug-2013.
Last one week high and low of the scrip stood at Rs. 147.50 and Rs. 115.80 respectively. The current market cap of the company is Rs. 2,293.00 crore.
The promoters holding in the company stood at 53.95% while Institutions and Non-Institutions held 26.50% and 19.55% respectively.
Jubilant Life Sciences’ wholly owned subsidiary - Jubilant First Trust Healthcare (JFTH), has sold its hospital business to Narayana Health. Anand Rathi Advisors were the Investment Bankers for the deal.
The business has been transferred on a going concern basis as a slump sale which will enable Jubilant Life Sciences to focus on its core businesses in Pharmaceuticals and Life Sciences. JFTH operates two hospitals in West Bengal, Kalpataru in Barasat and Rabindranath Thakur in Berhampore.
Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: